[ Back ] [ Bottom ]
90_SJ0035eng
90SJ0035 Engrossed LRB9005666JSgcB
1 SENATE JOINT RESOLUTION 35
2 (As amended by Senate Amendment No. 1)
3 WHEREAS, The General Assembly recognizes that cancer
4 clinical trials are designed to compare the effectiveness of
5 the standard medical treatment with a new therapy that
6 researchers believe will prove more effective, based on
7 scientific evidence and that such research provides the
8 foundation for improved patient care and decreased health
9 care costs; and
10 WHEREAS, The General Assembly recognizes that cancer
11 clinical trials involve a rigorously developed clinical
12 protocol that includes goals, rationale and background,
13 criteria for patient selection, specific directions for
14 administering therapy and monitoring patients, definition of
15 quantitative measures for determining treatment response, and
16 methods for documenting and treating adverse reactions; and
17 WHEREAS, The General Assembly recognizes that virtually
18 every major breakthrough for current standard medical
19 treatment has been developed through the clinical trial
20 system; and
21 WHEREAS, It is the intent of the General Assembly to
22 determine how the costs associated with cancer clinical
23 trials compare with the costs of standard therapy; therefore,
24 be it
25 RESOLVED, BY THE SENATE OF THE NINETIETH GENERAL ASSEMBLY
26 OF THE STATE OF ILLINOIS, THE HOUSE OF REPRESENTATIVES
27 CONCURRING HEREIN, that a Cancer Clinical Trials Task Force
28 is created; and be it further
29 RESOLVED, That with the assistance of a scientifically
30 recognized research facility, the Cancer Clinical Trials Task
31 Force shall review the claims and billing data from a sample
32 of the most current data available for Phase I, II, III, and
90SJ0035 Engrossed -2- LRB9005666JSgcB
1 IV cancer trial and non-trial patients, including a sample of
2 patients having lung, breast, prostate, colon, and ovarian
3 cancer; and be it further
4 RESOLVED, That patient privacy and confidentiality of
5 medical records shall be maintained; and be it further
6 RESOLVED, That the Cancer Clinical Trials Task Force
7 shall submit a report identifying and explaining any
8 incremental cost to the insurance industry that results from
9 cancer patients' participation in valid cancer clinical
10 trials to the Governor and General Assembly not later than
11 January 1, 1999; and be it further
12 RESOLVED, That on or before October 1, 1997, the
13 President of the Senate shall appoint 2 members of the Senate
14 to the Task Force, designating one member as co-chairperson,
15 the Minority Leader of the Senate shall appoint one member of
16 the Senate to the Task Force, the Speaker of the House of
17 Representatives shall appoint 2 members of the House to the
18 Task Force, designating one member as co-chairperson, and the
19 Minority Leader of the House of Representatives shall appoint
20 one member of the House to the Task Force; the Director of
21 Public Health, the Director of Insurance, and the Director of
22 Central Management or their respective designees shall serve
23 as ex-officio members of the Task Force; and the remainder of
24 the Task Force shall consist of 4 members of the public
25 appointed by the President of the Senate, 2 members of the
26 public appointed by the Minority Leader of the Senate, 4
27 members of the public appointed by the Speaker of the House
28 of Representatives, and 2 members of the public appointed by
29 the Minority Leader of the House of Representatives; and be
30 it further
31 RESOLVED, That the members of the Cancer Clinical Trials
32 Task Force shall serve without compensation, but may be
90SJ0035 Engrossed -3- LRB9005666JSgcB
1 reimbursed for their necessary expenses; and be it further
2 RESOLVED, That a copy of this resolution shall be
3 transmitted to the Directors of Public Health, Insurance, and
4 Central Management Services.
[ Top ]